Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke

Current Neurovascular Research

Volumn 11, Issue 1, 2014, Pages 62-67

  Chen, Hui ^a,b   Zhu, Guangming ^a   Liu, Nan ^a,b   Zhang, Weiwei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Outcome; Stroke; Thrombolysis; Time window; Tissue type plasminogen activator; Urokinase

Indexed keywords

ALTEPLASE; LUOXIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; GENDER; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEEDLE; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84898749651     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202610666131126150043     Document Type: Article

References (25)

1. Park H, Hwang GJ, Jin SC, Bang JS, Oh CW, Kwon OK. Intraarterial thrombolysis using double devices: mechanicomechanical or chemicomechanical techniques. J Korean Neurosurg Soc 2012; 51(2): 75-80.
2. Pan SM, Liu JF, Liu M, et al. Efficacy and Safety of a Modified Intravenous Recombinant Tissue Plasminogen Activator Regimen in Chinese Patients with Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 2013; 22(5): 690-3.
3. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 2007; 6(5): 456-64.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359(13): 1317-29.
5. Tekle WG, Chaudhry SA, Fatima Z, et al. Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. J Vasc Interv Neurol 2012; 5(1): 22-6.
6. Sarikaya H, Fischer A, Valko PO, et al. CT-based intravenous thrombolysis 3-4.5 hours after acute ischemic stroke in clinical practice. Neurol Res 2011; 33(7): 701-7.
7. Lee RS, Ok YC, Lim JS, Lim BC, Cho KY, Lee MC. Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke. Chonnam Med J 2012; 48(1): 52-6.
8. Zhou XY, Wang SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010; 17(8): 988-92.
9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. The New England journal of medicine 1995; 333(24): 1581-7.
10. Saver JL. Time is brain - quantified. Stroke 2006 Jan; 37(1): 263-6.
11. Chang R, Butman JA, Lonser RR, et al. Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation. J Vasc Interv Radiol 2013; 24(1): 27-34 e1.
12. Busl KM, Greer DM. Hypoxic-ischemic brain injury: pathophysiology, neuropathology and mechanisms. NeuroRehabilitation 2010; 26(1): 5-13.
13. Thurman RJ, Jauch EC, Panagos PD, Reynolds MR, Mocco J. Four evolving strategies in the emergent treatment of acute ischemic stroke. Emerg Med Pract 2012; 14(7): 1-26; quiz 26-7.
14. Bourekas EC, Slivka AP, Shah R, Sunshine J, Suarez JI. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery 2004; 54(1): 39-44; discussion 44-6.
15. Ji X, Meng R, Zhou J, Ling F, Jia J. Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis. Neurol Res 2006; 28(1): 46-9.
16. Walter S, Kostpopoulos P, Haass A, et al. Bringing the hospital to the patient: first treatment of stroke patients at the emergency site. PLoS One 2010; 5(10): e13758.
17. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30(12): 2598-605.
18. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369(9558): 275-82.
19. European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25(5): 457-507.
20. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M, Consortium SV. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009; 40(7): 2594-600.
21. Heldner M, Gralla J, Hungerbuhler H, Fischer U, Arnold M. [Acute occlusions of cerebral arterial vessels - intravenous versus intraarterial thrombolysis]. Ther Umsch 2012; 69(9): 511-6.
22. Vilas D, Gomis M, Blanco M, et al. Circadian Rhythms in the Efficacy of Intravenous Alteplase in Patients With Acute Ischemic Stroke and Middle Cerebral Artery Occlusion. Chronobiol Int 2012; 29(10): 1383-9.
23. Bratincsak A, Moore JW, El-Said HG. Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children: A single center experience. Catheter Cardiovasc Interv 2013; 82(5): 782-5.
24. Zareie H, Quain DA, Parsons M, et al. The influence of anterior cerebral artery flow diversion measured by transcranial Doppler on acute infarct volume and clinical outcome in anterior circulation stroke. Int J Stroke 2013; 8(4): 228-34.
25. Lev MH, Segal AZ, Farkas J, et al. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke 2001; 32(9): 2021-8.